Vicente E. Torres

Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.

The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein.

The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.

A complete mutation screen of the ADPKD genes by DHPLC.

Clinical profile of autosomal dominant polycystic liver disease.

The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1.

Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease.

PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression.

Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype.

A complete mutation screen of PKHD1 in autosomal-recessive polycystic kidney disease (ARPKD) pedigrees.

Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cells.

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia.

Analysis of the polycystins in aortic vascular smooth muscle cells.

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.

EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats.

Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat.

Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.

Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease.

Mutations in SEC63 cause autosomal dominant polycystic liver disease.

Therapies to slow polycystic kidney disease.

Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease.

Haplotype analysis improves molecular diagnostics of autosomal recessive polycystic kidney disease.

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

[Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype.

Vasopressin antagonists in polycystic kidney disease.

Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP).

The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat.

Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.

Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD).

Volume progression in polycystic kidney disease.

Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy.

Water for ADPKD? Probably, yes.

Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference.

Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases.

Duodenal diverticulosis in autosomal dominant polycystic kidney disease.

Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.

Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis.

Cerebral aneurysms.

Molecular diagnostics of Meckel-Gruber syndrome highlights phenotypic differences between MKS1 and MKS3.

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

Retinal arterial and venous occlusions in patients with ADPKD.

Autosomal dominant polycystic kidney disease.

Inferior vena cava stenting: a safe and effective treatment for intractable ascites in patients with polycystic liver disease.

Treatment of polycystic liver disease: one size does not fit all.

Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.

Quantitative assessment of hepatic fibrosis in an animal model with magnetic resonance elastography.

Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.

Increased occurrence of pericardial effusion in patients with autosomal dominant polycystic kidney disease.

Vasopressin directly regulates cyst growth in polycystic kidney disease.

Sirolimus reduces polycystic liver volume in ADPKD patients.

Role of vasopressin antagonists.

Vasopressin antagonists in polycystic kidney disease.

What the similarities of specific polycystic liver and kidney diseases can teach us about both.

Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.

Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.

Polycystic kidney disease.

Characterization of PKD protein-positive exosome-like vesicles.

Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.

MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement.

A case for water in the treatment of polycystic kidney disease.

Autosomal dominant polycystic kidney disease: the last 3 years.

Ciliary and centrosomal defects associated with mutation and depletion of the Meckel syndrome genes MKS1 and MKS3.

Type II calcimimetics and polycystic kidney disease: unanswered questions.

Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.

Vasopressin in chronic kidney disease: an elephant in the room?

Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney disease.

Cyclic nucleotide signaling in polycystic kidney disease.

The HALT polycystic kidney disease trials: design and implementation.

Treatment strategies and clinical trial design in ADPKD.

Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects.

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD.

Genetic variation of DKK3 may modify renal disease severity in ADPKD.

Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration.

Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

Medical and surgical treatment options for polycystic liver disease.

Germline PKHD1 mutations are protective against colorectal cancer.

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease.

B9D1 is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion analysis.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease.

Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas.

Fibrosis, regeneration, and aging: playing chess with evolution.

Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Epitope-tagged Pkhd1 tracks the processing, secretion, and localization of fibrocystin.

Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing.

Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors.

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.

Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation.

Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.

Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy.

Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease.

Tolvaptan in autosomal dominant polycystic kidney disease.

Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.

Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.

Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families.

Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease.

Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.

Transition fibre protein FBF1 is required for the ciliary entry of assembled intraflagellar transport complexes.

Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume.

Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD.

Novel methodology to evaluate renal cysts in polycystic kidney disease.

The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.

Supervised segmentation of polycystic kidneys: a new application for stereology data.

Phosphodiesterase 1A modulates cystogenesis in zebrafish.

Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.

Filling the holes in cystic kidney disease research.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Liver involvement in early autosomal-dominant polycystic kidney disease.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Blood pressure in early autosomal dominant polycystic kidney disease.

Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

Identification of Biomarkers for PKD1 Using Urinary Exosomes.

Vasopressin receptor antagonists, heart failure, and polycystic kidney disease.

Effects of hydration in rats and mice with polycystic kidney disease.

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.

Vasopressin and disruption of calcium signalling in polycystic kidney disease.

The Future of Polycystic Kidney Disease Research-As Seen By the 12 Kaplan Awardees.

Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease.

Volume regression of native polycystic kidneys after renal transplantation.

Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).